JLE

European Journal of Dermatology

MENU

A case of recurrent Stevens-Johnson syndrome caused by nivolumab therapy Ahead of print

Figures


  • Figure 1
Authors
1 Department of Dermatology, Gifu Prefectural Tajimi Hospital, Gifu,
2 Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya,
3 Department of Otorhinolaryngology, Gifu Prefectural Tajimi Hospital, Gifu, Japan

The anti-PD-1 antibody, nivolumab, is effective against a spectrum of malignancies including malignant melanoma, non-small cell lung cancer, and renal cell carcinoma.It has been reported that up to 22% of patients receiving anti-PD-1 therapy develop inflammatory skin lesions ranging from mild maculopapular lesions to severe Stevens-Johnson syndrome (SJS)-like rashes [1]. There have been several case reports of SJS and toxic epidermal necrolysis (TEN) during treatment with nivolumab [2-5].A 68-year-old [...]